<p><strong>Renal impairment</strong>: Lamivudine concentrations are increased in patients with moderate to severe renal impairment due to decreased clearance. The dose should therefore be adjusted.<br />
<br />
<strong>Adults and adolescents over 12 years</strong>:</p>

<ul>
	<li><strong>CrCl 50 ml/min</strong>: first dose 150 mg &amp;&nbsp;maintenance dose 150 mg twice daily</li>
	<li><strong>CrCl 30 to &lt;50&nbsp;ml/min</strong>:&nbsp;first dose 150 mg&nbsp;&amp;&nbsp;maintenance dose 150 mg once daily</li>
	<li><strong>CrCl 15 to 29&nbsp;ml/min</strong>: first dose 150 mg&nbsp;&amp;&nbsp;maintenance dose 100 mg once daily</li>
	<li><strong>CrCl 5 to 14&nbsp;ml/min</strong>:&nbsp;first dose 150 mg&nbsp;&amp;&nbsp;maintenance dose 50 mg once daily</li>
	<li><strong>CrCl &lt;5&nbsp;ml/min</strong>: first dose 50 mg&nbsp;&amp;&nbsp;maintenance dose 25 mg once daily</li>
</ul>

<p><strong>Hepatic Impairment</strong>: Data obtained in patients with moderate to severe hepatic impairment shows that Lamivudine pharmacokinetics are not significantly affected by&nbsp;hepatic dysfunction. Based on these data, no dose adjustment is necessary in patients with moderate or severe hepatic impairment unless accompanied by renal impairment.</p>